$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000139047819000030 Filed on May 15, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.638M	$2.500M	$3.880M
YoY Change	-46.26%	-35.57%	69.65%
% of Gross Profit
Research & Development	$1.381M	$1.859M	$1.804M
YoY Change	-13.25%	3.05%	-17.4%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.019M	$4.359M	$5.684M
YoY Change	-38.18%	-23.31%	27.13%
Operating Profit
YoY Change
Interest Expense	$20.00K	$10.00K	-$100.0K
YoY Change	-116.67%	-110.0%	-23.08%
% of Operating Profit
Other Income/Expense, Net	-$3.134M	-$190.0K	-$2.220M
YoY Change	-46.87%	-91.44%
Pretax Income	-$3.130M	-$4.540M	-$8.000M
YoY Change	-46.95%	-43.25%	73.91%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$3.134M	-$4.537M	-$7.995M
YoY Change	-48.3%	-43.25%	73.77%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.815M	-$10.09M	-$66.67M
COMMON SHARES
Basic Shares Outstanding	25.18M shares	23.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.80M	$2.600M	$3.500M
YoY Change	884.62%	-25.71%	-87.32%
Cash & Equivalents	$12.75M	$2.600M	$3.474M
Short-Term Investments
Other Short-Term Assets	$900.0K	$800.0K	$9.600M
YoY Change	-90.53%	-91.67%	-33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.64M	$3.416M	$13.07M
YoY Change	24.85%	-73.87%	-68.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$400.0K	$500.0K
YoY Change
Goodwill	$1.914M	$1.914M	$1.914M
YoY Change	0.0%	0.0%	-67.55%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$600.0K	$900.0K
YoY Change	-60.0%	-33.33%	800.0%
Total Long-Term Assets	$11.39M	$11.51M	$20.41M
YoY Change	-45.87%	-43.61%	-27.83%
TOTAL ASSETS
Total Short-Term Assets	$13.64M	$3.416M	$13.07M
Total Long-Term Assets	$11.39M	$11.51M	$20.41M
Total Assets	$25.03M	$14.93M	$33.49M
YoY Change	-21.7%	-55.42%	-52.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.762M	$4.638M	$11.45M
YoY Change	-68.91%	-59.5%	884.61%
Accrued Expenses	$1.276M	$807.0K	$4.470M
YoY Change	-74.35%	-81.95%	40.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$8.526M
YoY Change			-32.32%
Total Short-Term Liabilities	$5.400M	$5.804M	$25.75M
YoY Change	-78.27%	-77.46%	-29.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.150M
YoY Change		-100.0%
Other Long-Term Liabilities	$4.900M	$5.800M	$6.200M
YoY Change	-37.97%	-6.45%	416.67%
Total Long-Term Liabilities	$4.900M	$5.800M	$1.150M
YoY Change		404.35%	-4.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.400M	$5.804M	$25.75M
Total Long-Term Liabilities	$4.900M	$5.800M	$1.150M
Total Liabilities	$10.70M	$11.98M	$34.80M
YoY Change	-68.96%	-65.59%	-19.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$89.53M	-$86.39M	-$62.18M
YoY Change	31.19%	38.94%
Common Stock	$103.9M	$89.34M	$60.86M
YoY Change	57.95%	46.79%	-82.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.34M	$2.950M	-$1.318M
YoY Change
Total Liabilities & Shareholders Equity	$25.03M	$14.93M	$33.49M
YoY Change	-21.7%	-55.42%	-52.39%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$3.134M	-$4.537M	-$7.995M
YoY Change	-48.3%	-43.25%	73.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$4.660M	-$4.991M	-$5.403M
YoY Change	-26.03%	-7.63%	42.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net		$0.00	$589.0K
YoY Change		-100.0%
Cash From Financing Activities	14.83M	$2.230M	$4.739M
YoY Change	252.26%	-52.94%
NET CHANGE
Cash From Operating Activities	-4.660M	-$4.991M	-$5.403M
Cash From Investing Activities
Cash From Financing Activities	14.83M	$2.230M	$4.739M
Net Change In Cash	10.17M	-$2.761M	-$664.0K
YoY Change	-586.6%	315.81%	-82.54%
FREE CASH FLOW
Cash From Operating Activities	-$4.660M	-$4.991M	-$5.403M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25176475	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	SLS
CY2018Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	1881000	USD
CY2019Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	195000	USD
CY2018Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-3411000	USD
CY2019Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-387000	USD
CY2018Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-3411000	USD
CY2019Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-387000	USD
CY2019Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	195000	USD
CY2019Q1	gale	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	2150000	shares
CY2019Q1	gale	Class Of Warrant Or Right Number Of Warrants Issued ClassOfWarrantOrRightNumberOfWarrantsIssued	2150000	shares
CY2019Q1	gale	Classof Warrantor Right Canceled Or Expired ClassofWarrantorRightCanceledOrExpired	0	shares
CY2017Q4	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P5Y
CY2019Q1	gale	Closing Price Of Common Stock ClosingPriceOfCommonStock	1.02
CY2019Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	265000	shares
CY2018Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	4326000	USD
CY2019Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	4713000	USD
CY2018Q4	gale	Contract Research Payable ContractResearchPayable	858000	USD
CY2019Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	991000	USD
CY2018Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1013000	USD
CY2019Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	991000	USD
CY2019Q1	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	0	USD
CY2019Q1	gale	Fair Value Of Warrants Exercise Price Adjustment FairValueOfWarrantsExercisePriceAdjustment	173000	USD
CY2018Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1013000	USD
CY2017Q4	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	5.60
CY2018Q4	gale	In Process Research Development InProcessResearchDevelopment	8500000	USD
CY2019Q1	gale	Contract Research Payable ContractResearchPayable	184000	USD
CY2018Q1	gale	Conversionwith Series A Convertible Preferred Stock ConversionwithSeriesAConvertiblePreferredStock	1968000	USD
CY2019Q1	gale	Conversionwith Series A Convertible Preferred Stock ConversionwithSeriesAConvertiblePreferredStock	0	USD
CY2018Q1	gale	Convertible Preferred Stock Dividends ConvertiblePreferredStockDividends	72000	USD
CY2018Q1	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	0	USD
CY2019Q1	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	439000	USD
CY2019Q1	gale	Dividend Modification Of Warrants DividendModificationOfWarrants	173000	USD
CY2018Q1	gale	Dividend On Conversion Of Series A Convertible Preferred Stock DividendOnConversionOfSeriesAConvertiblePreferredStock	1968000	USD
CY2019Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	1700000	USD
CY2019Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y9M3D
CY2019Q1	gale	Fair Value Of Warrants Canceled FairValueOfWarrantsCanceled	0	USD
CY2019Q1	gale	In Process Research Development InProcessResearchDevelopment	8500000	USD
CY2018Q1	gale	Increase Decrease In Fair Value Of Warrant Liability IncreaseDecreaseInFairValueOfWarrantLiability	0	USD
CY2019Q1	gale	Increase Decrease In Fair Value Of Warrant Liability IncreaseDecreaseInFairValueOfWarrantLiability	173000	USD
CY2019Q1	gale	Lessee Operating Lease Amortization LesseeOperatingLeaseAmortization	100000	USD
CY2019Q1	gale	Lessee Operating Lease Lease Term LesseeOperatingLeaseLeaseTerm	P1Y3M29D
CY2018Q1	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	888000	USD
CY2019Q1	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	0	USD
CY2018Q1	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	685000	USD
CY2019Q1	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	0	USD
CY2018Q1	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	685000	USD
CY2019Q1	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	0	USD
CY2019Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	362000	shares
CY2018Q4	gale	Rebates And Returns Of Former Commercial Products RebatesAndReturnsOfFormerCommercialProducts	138000	USD
CY2019Q1	gale	Rebates And Returns Of Former Commercial Products RebatesAndReturnsOfFormerCommercialProducts	0	USD
CY2018Q1	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	285000	USD
CY2019Q1	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	0	USD
CY2019Q1	gale	Restricted Stock Shares Reservedfor Future Issuance RestrictedStockSharesReservedforFutureIssuance	13000	shares
CY2019Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
CY2019Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2018Q1	gale	Warrant Exchange Agreements Amount WarrantExchangeAgreementsAmount	285000	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	5400000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3755000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4638000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2219000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	807000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	540000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	291000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	87098000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	89340000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-1968000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	22000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	185000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2587000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	185000	USD
CY2018Q4	us-gaap	Assets Assets	16915000	USD
CY2019Q1	us-gaap	Assets Assets	14927000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	5838000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	3416000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5337000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2600000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12750000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12086000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5451000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2690000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-664000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2761000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.42
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	316163	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17698000	shares
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17698000	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19671000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22026476	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24176475	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22026476	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24176475	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2018Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1631000	USD
CY2019Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	5684000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	4359000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	357000	USD
CY2019Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	357000	USD
CY2018Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	663000	USD
CY2019Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	626000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	224000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14927000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5974000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.67
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	675000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	332000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1881000	USD
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-195000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	1914000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	1914000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7995000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4537000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-240000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	883000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1197000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1412000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	622000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	302000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-96000	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	14000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	110000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	508000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	284000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	37000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	11670000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	11977000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16915000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5804000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4739000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2230000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5403000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4991000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7995000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4537000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9963000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4976000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	471000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	359000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	471000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	601000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	377000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	224000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2018Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2311000	USD
CY2019Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-178000	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	20000	USD
CY2019Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2018Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1968000	USD
CY2019Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	387000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	726000	USD
CY2018Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	34000	USD
CY2019Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	14000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	5328000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2230000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	589000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1804000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1859000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	114000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	114000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	114000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	114000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81855000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86392000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3880000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2500000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	22000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	185000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8005
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9657
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0271
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0249
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	123000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	107.54
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	940000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.70
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	395000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1333000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.09
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.94
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.24
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.38
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M16D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M15D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y0M4D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7M6D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2019Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1631000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5328000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2230000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	5245000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	2950000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2070000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1318000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5245000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2950000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5952193	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22368142	shares

Files In Submission

Name	View Source	Status
0001390478-19-000030-index-headers.html	Edgar Link	pending
0001390478-19-000030-index.html	Edgar Link	pending
0001390478-19-000030.txt	Edgar Link	pending
0001390478-19-000030-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20190331.xml	Edgar Link	completed
gale-20190331.xsd	Edgar Link	pending
gale-20190331_cal.xml	Edgar Link	unprocessable
gale-20190331_def.xml	Edgar Link	unprocessable
gale-20190331_lab.xml	Edgar Link	unprocessable
gale-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sellas-logoa09.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
sls-20190331x10q.htm	Edgar Link	pending
sls20190331ex311.htm	Edgar Link	pending
sls20190331ex312.htm	Edgar Link	pending
sls20190331ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2019 Q2 Form 10-Q Financial Statement

#000139047819000030 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2019 Q2 Form 10-Q Financial Statement

#000139047819000030 Filed on May 15, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls